Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (31151)	9/11/2002 9:12:08 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 32384

Good NEWS from LGND... Ligand Earns Two Milestones as Wyeth Advances Early-Stage Products for Women's Health NSP-989 Enters Clinical Development for Contraception, HRT; Back-Up Compound Moves into Late Pre-Clinical Studies Wednesday September 11, 7:47 pm ET SAN DIEGO--(BUSINESS WIRE)--Sept. 11, 2002-- Ligand Pharmaceuticals (Nasdaq: LGND - News) has earned two undisclosed milestone payments from its corporate partner Wyeth (NYSE: WYE - News), which has begun clinical development of NSP-989 for contraception and hormone replacement therapy (HRT) and advanced a back-up compound into late pre-clinical testing. NSP-989 is a non-steroidal progestin resulting from Ligand's research collaboration with Wyeth. Wyeth's Investigational New Drug application (IND) for NSP-989 recently cleared its FDA waiting period.